Form 4: Arcadia Biosciences CEO Thomas Schaefer Reports Stock Purchase

Arcadia Biosciences CEO Thomas Schaefer reports the purchase of 700 shares of common stock at $2.49 per share through the company's Employee Stock Purchase Plan.

Summary

• On February 3, 2025, Thomas J. Schaefer, CEO of Arcadia Biosciences, Inc. (RKDA), purchased 700 shares of the company's common stock.
• The purchase was made at a price of $2.49 per share.
• The transaction was conducted through the company's 2015 Employee Stock Purchase Plan (ESPP).
• Following the transaction, Schaefer directly owns 2,819 shares of Arcadia Biosciences common stock.
• The shares were purchased at 85% of the closing price of Arcadia's common stock, as per the ESPP terms.
• The reported amount includes ESPP purchases from February 1, 2021, to February 1, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's stock purchase, indicating confidence in the company. However, it's a routine transaction under the ESPP, limiting the impact.

Positives

• The CEO's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
• The Employee Stock Purchase Plan allows employees to purchase shares at a discounted price, aligning their interests with those of the shareholders.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. Purchases by executives are generally viewed positively.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Arcadia Biosciences, RKDA, Thomas J. Schaefer, CEO, stock purchase, Employee Stock Purchase Plan, ESPP, Form 4, insider trading